InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（2 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
2
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Explore the detailed record of transactions filed by Agarwal Sunil, Directeur du Développement et Directeur Marketing. Insider active across 3 companies, notably Sana Biotechnology, Inc.. Cumulatively, 6 filings have been recorded. Split: 0 buy · 2 sells. Total volume traded: €1.3m. History available since 15 September 2021. The latest transaction was filed on 25 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Agarwal Sunil
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
16,025 股0Common StockSEC:0001655759-25-000126:0
5,899 股0Common StockSEC:0001655759-24-000084:0
8,242 股0Common StockSEC:0001655759-23-000059:0
58,373 股@ US$26.0695100.0% 占其流量Common StockSEC:0001562180-21-005999:0
456 股Common StockSEC:0001562180-16-001371:0
585 股Common StockSEC:0001562180-16-001371:1
6 条申报中的 6 条
About Agarwal Sunil
AGARWAL SUNIL is Director of Development and Marketing Director. He has 6 filings in total, and across the sampled recent filings, the reported sell volume is 1287441 EUR, covering the period from 2016-01-21 to 2025-06-30. The companies mentioned are Arvinas, INC., Ultragenyx Pharmaceutical Inc. and Sana Biotechnology, Inc., and the modal transaction nature is Attribution.
